COLORADO SPRINGS, Colorado,
Sept. 29, 2014 /PRNewswire/ --
Cannabis Science, Inc. (OTCQB: CBIS), a U.S. Company specializing
in cannabis formulation-based drug development and related
consulting, has entered into a laboratory services agreement with
ImmunoClin Corporation (IMCL) through its wholly-owned UK
subsidiary, ImmunoClin Ltd., a healthcare company with over
thirteen years' experience in providing premiere laboratory and
related pre-clinical and clinical research services on a commercial
scale.
"With ImmunoClin's track record in assisting biotech, pharma and
food companies as well as public institutions in pharmaceutical and
nutraceutical development projects, we are excited to initiate this
long-term relationship between ImmunoClin and CBIS in the
cannabinoid research field. We further benefit from the fact
that ImmunoClin's founder, Dr. Dorothy
Bray, is a clinical development expert and serves at present
as the Director, President and CEO of both Companies, thereby
assuring smooth and effective collaboration," stated Mr.
Mario S. Lap, Director and President
of European Operations, Cannabis Science, Inc.
"With the contract in place, we intend to move quickly and
efficiently to assist Cannabis Science in developing proprietary
formulations to bring its cannabinoid based products to patients in
need," said Khadija Benlhassan, Ph.D., Director and Chief
Scientific Officer, ImmunoClin Corporation.
Cannabis Science anticipates that ImmunoClin will commence
cannabinoid-based drug formulation at its laboratories within the
coming weeks, including advanced development of Cannabis Science's
proprietary neurological drug, tentatively designated as
"CS-Neuro-1". This contract complements the Company's agricultural
and research programs in Spain,
Italy and other European
countries.
"Cannabis Science looks forward to working with ImmunoClin in
the development of CS-Neuro-1, CS-TATI-1, CS-S/BCC-1, and other
products in the Cannabis Science pipeline that we strongly believe
will improve the lives of people around the world," concluded Mr.
Lap.
About ImmunoClin Corporation
ImmunoClin Corporation is a United
States healthcare company with principal office in
Washington, DC, USA, European
headquarters and laboratory facilities in London, United Kingdom and laboratories in
central Paris, France.
ImmunoClin concentrates its innovation on developing personalized
and preventive strategies to fight inflammatory conditions that are
the underlying cause of pathologies in multiple conditions
affecting the majority of the human population: infections,
cancer, cardiovascular disease, and dementia, including Alzheimer's
disease. In addition, ImmunoClin provides select third-party
companies with specialized laboratory and research services.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique
understanding of metabolic processes to provide novel treatment
approaches to a number of illnesses for which current treatments
and understanding remain unsatisfactory. Cannabinoids have an
extensive history dating back thousands of years, and currently
there are a growing number of peer-reviewed scientific publications
that document the underlying biochemical pathways that cannabinoids
modulate. The Company works with leading experts in drug
development, medicinal characterization, and clinical research to
develop, produce, and commercialize novel therapeutic approaches
for the treatment for illnesses caused by infections as well as for
age-related illness. Our initial focus is on skin cancers and
neurological conditions.
Forward Looking Statements
This Press Release includes
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Act of
1934. A statement containing words such as "anticipate," "seek,"
intend," "believe," "estimate," "expect," "project," "plan," or
similar phrases may be deemed "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. Some or all of the events or results anticipated by these
forward-looking statements may not occur. Factors that could cause
or contribute to such differences include the future U.S. and
global economies, the impact of competition, and the Company's
reliance on existing regulations regarding the use and development
of cannabis-based drugs. Cannabis Science, Inc., does not undertake
any duty nor does it intend to update the results of these
forward-looking statements.
Cannabis Science, Inc.
Dr. Dorothy Bray, CEO &
Director
www.cannabisscience.com
dorothy.bray@cannabisscience.com
info@cannabisscience.com
Tel: 1.888.777.0658
Investment Inquiries
Robert Kane, CFO & Director
robert.kane@cannabisscience.com
Tel: 1.561.420.4824
Cannabis Science, Inc.
Raymond C. Dabney, Management
Consultant, Co-Founder
raymond@cannabisscience.com
Tel: 1.310.650.3788